Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + cisplatin + tislelizumab + ociperlimab
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
GP + PD-1-Fudan University-biliary tract carcinoma refers to a combination chemo-immunotherapy regimen being investigated by Fudan University for the first-line treatment of advanced biliary tract carcinoma. This regimen, evaluated in the Phase 2 ZSAB-TOP trial, consists of the chemotherapy doublet gemcitabine and cisplatin (GP) combined with two immune checkpoint inhibitors: tislelizumab, a monoclonal antibody targeting programmed cell death protein 1 (PD-1), and ociperlimab, a monoclonal antibody targeting T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT). The combination aims to leverage the cytotoxic effects of chemotherapy to release tumor antigens while simultaneously blocking multiple inhibitory pathways (PD-1 and TIGIT) to restore and enhance the anti-tumor immune response.
- Other names
- GP + Tislelizumab + OciperlimabGP+PD-1+TIGITGP+PD-1+TightGP + PD-1-Fudan University-biliary tract carcinoma
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TIGIT (T cell immunoreceptor with Ig and ITIM domains)RNR (Ribonucleotide reductase)DNADNA polymerase family
Beyond the preview
Go deeper on gemcitabine + cisplatin + tislelizumab + ociperlimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + cisplatin + tislelizumab + ociperlimab.